News

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Resverlogix to spin-out RVX Thera to unlock epigenetics platform value

10-04-2013

Canadian drugmaker Resverlogix (TSX:RVX), which is exploring a sale, says that its board of directors…

ApolipoproteinBiotechnologyImmunologicalsMergers & AcquisitionsOncologyResverlogixRVX TherapeuticsRVX-208

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

05-02-2013

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired…

Aduro BioTechAspen PharmacareBioSante PharmaceuticalsBiotechnologyGenericsGVAXImmunologicalsMerck & CoMergers & AcquisitionsOncologyVaccines

Emergent BioSolutions to buy Trubion Pharma for up to $135.5 million; reaffirms 2010 guidance

16-08-2010

US vaccine maker Emergent BioSolutions has entered into a definitive agreement to acquire Trubion Pharmaceuticals,…

BiotechnologyEmergent BioSolutionsImmunologicalsMergers & AcquisitionsOncologyPharmaceuticalTrubion PharmaceuticalsVaccines

Abbott Labs bids $722 for Facet to enhances its biotech R&D pipeline, including daclizumab

10-03-2010

US health care major Abbott Laboratories has signed a definitive agreement for Abbott to acquire Facet…

BiotechnologyImmunologicalsMergers & AcquisitionsOncologyPharmaceutical

Eisai exercises option to buy AkaRx, for $255, along with rights to thrombocytopenia drug AKR-501

21-12-2009

Japanese drug major Eisai has said it will initiate procedures to acquire New Jersey, USA-based AkaRx…

EisaiImmunologicalsMergers & AcquisitionsMGI PharmaNorth AmericaOncologyPharmaceutical

COMPANY SPOTLIGHT

Menarini

Back to top